FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma By Ogkologos - January 28, 2026 99 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRANSCEND FL-MZL Cohort Source RELATED ARTICLESMORE FROM AUTHOR FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology Immune Pathways Help Identify Patients with Cancer and HIV Most Likely to Experience Reservoir Decay with Anti-PD1 Therapy MOST POPULAR Reducing Health Care Disparities Through Cancer Clinical Trials November 30, 2020 How do we die of cancer? What we know (and what... May 8, 2022 Higher Risk of Invasive Behaviour for Oncogenic Fusions–Driven Paediatric Thyroid Cancers January 21, 2022 Rare Disease Day: Raising Awareness for Rare Cancers February 26, 2021 Load more HOT NEWS Adagrasib Shows Promising Activity as Monotherapy, Even Greater in Combination with... Cancer in My Community: Caring for Children With Cancer in Paraguay FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma A 27-Year-Old Woman Passed Away. The Note She Wrote The Day...
